Get the Stockscreener App
18.87
10.09%
1.73
Scilex Holding Company stock is traded at $18.87, with a volume of 464.92K.
It is up +10.09% in the last 24 hours and up +113.46% over the past month.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
See More
Previous Close:
$17.14
Open:
$17.32
24h Volume:
464.92K
Relative Volume:
2.56
Market Cap:
$131.25M
Revenue:
$46.74M
Net Income/Loss:
$-114.33M
P/E Ratio:
-14.63
EPS:
-1.29
Net Cash Flow:
$-21.04M
1W Performance:
+4.37%
1M Performance:
+113.46%
6M Performance:
+63.48%
1Y Performance:
-55.81%
1-Day Range:
$17.32
$20.41
1-Week Range:
$15.61
$20.41
52-Week Range:
$3.60
$45.15
Scilex Holding Company Stock (SCLX) Company Profile
Name
Scilex Holding Company
Sector
Industry
Phone
(650) 516-4310
Address
960 SAN ANTONIO ROAD, PALO ALTO
Compare SCLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
18.87 | 134.80M | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-25 | Initiated | D. Boral Capital | Buy |
| Oct-16-24 | Initiated | Alliance Global Partners | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-16-23 | Initiated | B. Riley Securities | Buy |
| Oct-13-23 | Initiated | B. Riley Securities | Buy |
| Oct-09-23 | Initiated | H.C. Wainwright | Buy |
View All
Scilex Holding Company Stock (SCLX) Latest News
AI Trend Models Suggest Bounce for Scilex Holding CompanyWeekly Trading Summary & Low Volatility Stock Suggestions - thegnnews.com
Scilex Holding Company Forms Bullish Flag — Upside Ahead2025 Market Sentiment & AI Enhanced Execution Alerts - newsyoung.net
How Scilex Holding Company stock performs during market volatilityPortfolio Risk Summary & Fast Gaining Stock Reports - beatles.ru
Quantitative breakdown of Scilex Holding Company recent move2025 Short Interest & Stock Market Timing Techniques - Newser
Tools to monitor Scilex Holding Company recovery probabilityTrade Analysis Summary & Short-Term High Return Strategies - Newser
Is a relief rally coming for Scilex Holding Company Equity Warrant holdersTrade Risk Report & Smart Money Movement Alerts - Newser
Published on: 2025-08-17 02:16:52 - Newser
Combining machine learning predictions for Scilex Holding Company Equity Warrant2025 Market Overview & Daily Price Action Insights - Newser
Chart overlay techniques for tracking Scilex Holding Company Equity Warrant2025 Top Decliners & Consistent Return Investment Signals - Newser
Using R and stats models for Scilex Holding Company forecastingWeekly Profit Analysis & Consistent Growth Equity Picks - Newser
Full technical analysis of Scilex Holding Company Equity Warrant stockTrade Exit Report & Low Drawdown Trading Strategies - Newser
Long term hold vs stop loss in Scilex Holding Company Equity WarrantQuarterly Profit Review & Short-Term High Return Ideas - Newser
Using Python tools to backtest Scilex Holding Company strategies2025 Top Decliners & Consistent Return Investment Signals - Newser
How Scilex Holding Company Equity Warrant stock performs during market volatility2025 Winners & Losers & Verified Swing Trading Watchlists - Newser
Using Ichimoku Cloud for Scilex Holding Company Equity Warrant technicalsPortfolio Return Report & Precise Trade Entry Recommendations - Newser
Risk adjusted return profile for Scilex Holding Company Equity Warrant analyzedWeekly Loss Report & AI Driven Price Predictions - Newser
Can trapped investors hope for a rebound in Scilex Holding Company Equity WarrantEarnings Miss & Risk Managed Trade Strategies - Newser
Scilex Holding Company Equity Warrant’s volatility index tracking explainedWeekly Gains Summary & Weekly Sector Rotation Insights - Newser
How Efficient Is Scilex Holding Company at Controlling Operating CostsWeekly Stock Report & Daily Oversold Bounce Ideas - Newser
Is Scilex Holding Company meeting your algorithmic filter criteriaGap Up & Verified Entry Point Signals - Newser
Scilex Holding Company Equity Warrant stock momentum explainedWeekly Trend Report & Safe Entry Point Identification - Newser
Can momentum traders help lift Scilex Holding CompanyPortfolio Value Report & Low Risk High Win Rate Stock Picks - Newser
Can swing trading help recover from Scilex Holding Company Equity Warrant lossesWeekly Market Outlook & Stepwise Trade Signal Implementation - Newser
Scilex gains on spinoff plans for pharma subsidiary - MSN
Intraday pattern recognizer results for Scilex Holding Company Equity Warrant - Newser
Scilex Holding Soars 20.81% on SEC Approval, Funding, Partnership - AInvest
Scilex Holding Company Equity Warrant Stock Lags Behind Sector BenchmarksJuly 2025 Chart Watch & Free Low Drawdown Momentum Trade Ideas - beatles.ru
Scilex (NASDAQ:SCLXW) Stock Price Up 11.5% – Should You Buy? - Defense World
Scilex Holding Company shares fall 1.14% after-hours as SEC declares effectiveness of S-4 filing for Denali-Semnur merger. - AInvest
Scilex Holding Company ($SCLX) Stock: Surges Over 17% as SEC Clears Path for Denali-Semnur Merger Vote in September - CoinCentral
Scilex Holding shares surge 13.84% intraday after SEC approves Denali Capital Acquisition Corp. and Semnur Pharmaceuticals merger. - AInvest
Scilex Holding Company shares rise 6.34% premarket after announcing $100 million in funding from Tumim Stone Capital. - AInvest
Scilex Holding Company Announces S-4 Effectiveness, Denali-Semnur Merger Proposal, and Oramed Pharmaceuticals Enters Option Agreement with Scilex - AInvest
Scilex announces S-4 effectiveness for Denali-Semnur merger proposal - MarketScreener
Scilex says registration statement on Form S-4 declared effective by SEC - TipRanks
Scilex Holding Company (Nasdaq: SCLX) Announces Effectiveness of Registration Statement on Form S-4 for the Proposed Business Combination of Denali Capital Acquisition Corp. and Semnur Pharmaceuticals, Inc., a Majority-Owned Subsidiary of Scilex - GlobeNewswire
Denali's registration statement declared effective, extraordinary meeting scheduled. - AInvest
Scilex Announces Effectiveness of Registration Statement for Proposed Business Combination with Semnur Pharmaceuticals - AInvest
Analysts Apply Wyckoff Model to Scilex Holding Company StockWeekly Trade Review & High Return Trade Opportunity Guides - beatles.ru
Tick level data insight on Scilex Holding Company volatilityBuy Alert Based on RSI and Volume - Newser
Scilex Holding Co expected to post a loss of 91 cents a shareEarnings Preview - TradingView
Scilex (SCLX) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Scilex Holding Company Equity Warrant Company’s Quarterly Earnings Growth: What the Numbers SayFree Real Profit Trade Plan Suggestions - Newser
Scilex Holding SCLX 2025Q2 Earnings Preview Upside Potential on Robust Revenue Growth - AInvest
Scilex Holding WRT SCLXW Q2 2025 Earnings Preview Upside Potential on Improved Cost Management - AInvest
Is Scilex Holding Company Equity Warrant stock a growth or value playFree Capital Protection Trading Strategies - Newser
Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC - The Globe and Mail
Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication - The Globe and Mail
Should you wait for a breakout in Scilex Holding Company Equity WarrantShort Term Momentum Based Trading Strategy - Newser
Competitive Positioning of Scilex Holding Company: Is It Leading or LaggingAlpha Stock Picks with Chart Confirmation - Newser
Scilex Holding Company stock trendline breakdownFree Fast Entry High Potential Stock Alerts - Newser
Scilex Holding Company Stock (SCLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Scilex Holding Company Stock (SCLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ji Henry | Executive Chairperson |
Oct 31 '24 |
Buy |
0.94 |
8,888 |
8,351 |
320,161 |
| SHAH JAISIM | See Remarks |
Oct 29 '24 |
Buy |
0.99 |
32,000 |
31,670 |
109,333 |
| Followwill Dorman | Director |
Oct 18 '24 |
Buy |
0.99 |
1,000 |
990 |
2,300 |
| Chun Jay | Director |
Oct 18 '24 |
Buy |
0.95 |
5,000 |
4,750 |
112,500 |
| Wu Yue Alexander | Director |
Oct 17 '24 |
Buy |
0.95 |
20,000 |
18,992 |
25,000 |
| Lemus David | Director |
Oct 17 '24 |
Buy |
0.90 |
2,000 |
1,800 |
2,000 |
| Ji Henry | Executive Chairperson |
Oct 17 '24 |
Buy |
0.97 |
10,000 |
9,710 |
60,070 |
| SHAH JAISIM | See Remarks |
Oct 16 '24 |
Buy |
0.99 |
30,000 |
29,751 |
77,333 |
| Ma Stephen Hoi | Chief Financial Officer |
Oct 16 '24 |
Buy |
0.97 |
6,700 |
6,499 |
22,840 |
1.46%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):